A Virginia dialysis patient with end-stage renal failure on Wednesday received a bioengineered blood vessel implant in the first U.S. trial of the treatment. The study eventually will include 20 patients who will be given lab-grown vein implants. The vessels are designed to hasten blood flow during hemodialysis.

Full Story:

Related Summaries